Skip to main navigation
Skip to main content

Main Utility

  • Patients & Caregivers
  • Healthcare Professionals
  • Clinical Trials
  • Presentation & Publications
  • Investors & News
twitter linkedin

Main navigation

  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • DCC-3116
    • Preclinical Pipeline
    • Expanded Access
  • Our Medicine
    • QINLOCK® (ripretinib)
  • Who We Are
    • Management
  • Join Us
    • Open Positions

Main navigation

  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • DCC-3116
    • Preclinical Pipeline
    • Expanded Access
  • Our Medicine
    • QINLOCK® (ripretinib)
  • Who We Are
    • Management
  • Join Us
    • Open Positions

Main Utility

  • Patients & Caregivers
  • Healthcare Professionals
  • Clinical Trials
  • Presentation & Publications
  • Investors & News
twitter linkedin

Contact IR

Investor Relations
  • Overview
  • Press Releases
  • Events and Presentations
  • Historical Price Lookup
  • SEC Filings
  • Corporate Governance
    • Documents and Charters
    • Management
    • Board of Directors
  • Investor Resources
    • FAQs
    • Contact IR
    • Email Alerts

Investor Relations Contact:

Argot Partners
Investor Relations
Maghan Meyers
212-600-1902
deciphera@argotpartners.com

  • Print

    Print
  • RSS Feeds

    RSS Feeds
  • Email Alerts

    Email Alerts
  • Contact IR

    Contact IR

twitter linkedin
Contact us

Main navigation

  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • DCC-3116
    • Preclinical Pipeline
    • Expanded Access
  • Our Medicine
    • QINLOCK® (ripretinib)
  • Who We Are
    • Management
  • Join Us
    • Open Positions

Footer Utility

  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Web Accessibility Statement

© 2024 Deciphera Pharmaceuticals, Inc. QINLOCK and the QINLOCK logo are registered trademarks of Deciphera Pharmaceuticals, LLC. Deciphera and the Deciphera logo are trademarks of Deciphera Pharmaceuticals, LLC.